ADCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ADC Therapeutics SA (ADCT) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock is experiencing significant negative sentiment, poor trial results, insider selling, and potential legal issues. Additionally, technical indicators and options data suggest bearish trends, and there are no strong positive catalysts to offset these risks.
The stock is in a bearish trend with the MACD histogram below 0 and negatively contracting. The RSI is at 22.945, indicating oversold conditions, but this is not a clear buy signal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its support level of 1.072.
NULL identified. There are no recent positive developments or catalysts for the stock.
Underwhelming LOTIS-5 trial results with significant death imbalance and modest benefits.
Insider selling has increased by 1160.65% over the last month.
Legal investigation by Pomerantz LLP for potential securities fraud and unlawful business practices.
Downgraded analyst ratings and reduced price targets.
No financial data available for analysis. However, the lack of valuation data and the negative sentiment surrounding the company indicate potential financial instability.
Analysts have downgraded the stock significantly. RBC Capital downgraded the stock to Sector Perform with a price target of $2 (down from $6), citing regulatory risks and modest trial benefits. Stephens lowered the price target to $5 (from $8) and sees the LOTIS-5 results as net-negative. H.C. Wainwright previously raised the price target to $8 in March, but this is outdated given recent developments.
